These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29175871)

  • 1. Structure and function of RET in multiple endocrine neoplasia type 2.
    Plaza-Menacho I
    Endocr Relat Cancer; 2018 Feb; 25(2):T79-T90. PubMed ID: 29175871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular advances in medullary thyroid cancer diagnostics.
    Hubner RA; Houlston RS
    Clin Chim Acta; 2006 Aug; 370(1-2):2-8. PubMed ID: 16519882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current concepts in RET-related genetics, signaling and therapeutics.
    Plaza-Menacho I; Burzynski GM; de Groot JW; Eggen BJ; Hofstra RM
    Trends Genet; 2006 Nov; 22(11):627-36. PubMed ID: 16979782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
    Krampitz GW; Norton JA
    Cancer; 2014 Jul; 120(13):1920-31. PubMed ID: 24699901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of rapid and accurate screening test for RET hotspot somatic and germline mutations in MEN2 syndromes.
    Zupan A; Glavač D
    Exp Mol Pathol; 2015 Dec; 99(3):416-25. PubMed ID: 26321248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations.
    Margraf RL; Crockett DK; Krautscheid PM; Seamons R; Calderon FR; Wittwer CT; Mao R
    Hum Mutat; 2009 Apr; 30(4):548-56. PubMed ID: 19177457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
    Iervolino A; Iuliano R; Trapasso F; Viglietto G; Melillo RM; Carlomagno F; Santoro M; Fusco A
    Cancer Res; 2006 Jun; 66(12):6280-7. PubMed ID: 16778204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.
    Gujral TS; Mulligan LM
    Ann N Y Acad Sci; 2006 Aug; 1073():234-40. PubMed ID: 17102091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium.
    Machens A; Lorenz K; Sekulla C; Höppner W; Frank-Raue K; Raue F; Dralle H
    Eur J Endocrinol; 2013 Mar; 168(3):307-14. PubMed ID: 23211574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.
    Grey W; Hulse R; Yakovleva A; Genkova D; Whitelaw B; Solomon E; Diaz-Cano SJ; Izatt L
    Endocr Pathol; 2017 Mar; 28(1):41-48. PubMed ID: 27704398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
    Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
    Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of RET with multiple endocrine neoplasia type 2.
    Zhang M; Liu Y; Fu J; Hu Y; Sun Z
    J Cancer Res Ther; 2017; 13(5):823-828. PubMed ID: 29237911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inducible dimerization of RET reveals a specific AKT deregulation in oncogenic signaling.
    Frêche B; Guillaumot P; Charmetant J; Pelletier L; Luquain C; Christiansen D; Billaud M; Manié SN
    J Biol Chem; 2005 Nov; 280(44):36584-91. PubMed ID: 16123037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
    Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I
    Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unexpected structures formed by the kinase RET C634R mutant extracellular domain suggest potential oncogenic mechanisms in MEN2A.
    Liu Y; De Castro Ribeiro O; Haapanen O; Craven GB; Sharma V; Muench SP; Goldman A
    J Biol Chem; 2022 Oct; 298(10):102380. PubMed ID: 35985422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple endocrine neoplasia type 2.
    Marini F; Falchetti A; Del Monte F; Carbonell Sala S; Tognarini I; Luzi E; Brandi ML
    Orphanet J Rare Dis; 2006 Nov; 1():45. PubMed ID: 17105651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A.
    Chung YJ; Kim HH; Kim HJ; Min YK; Lee MS; Lee MK; Kim KW; Ki CS; Kim JW; Chung JH
    Thyroid; 2004 Oct; 14(10):813-8. PubMed ID: 15588376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
    Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
    Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.
    Romei C; Mariotti S; Fugazzola L; Taccaliti A; Pacini F; Opocher G; Mian C; Castellano M; degli Uberti E; Ceccherini I; Cremonini N; Seregni E; Orlandi F; Ferolla P; Puxeddu E; Giorgino F; Colao A; Loli P; Bondi F; Cosci B; Bottici V; Cappai A; Pinna G; Persani L; Verga U; Boscaro M; Castagna MG; Cappelli C; Zatelli MC; Faggiano A; Francia G; Brandi ML; Falchetti A; Pinchera A; Elisei R;
    Eur J Endocrinol; 2010 Aug; 163(2):301-8. PubMed ID: 20516206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.